Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
31. |
ECCT/25/05/05 | Hibiscus 2 - Site 252 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Videlis Nduba Site(s) in Kenya 1. KEMRI CRDR Siaya Clinical Research Annex (Siaya county) |
15-10-2025 |
View |
32. |
ECCT/25/05/12 | SAFIRE A multicentre open-label, non-inferiority adaptive platform randomised controlled trial to evaluate the efficacy, safety, and tolerability of antimalarials for the treatment of uncomplicated malaria in the first trimester of pregnancy |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya The Kenya Medical Research Institute (KEMRI), Centre for Global Health Research (CGHR) |
15-10-2025 |
View |
33. |
ECCT/25/05/04 | Floral roll over study An open-label, multi-centre, rollover study to characterise long-term safety and efficacy of etavopivat in adults, adolescents and children who have sickle cell disease or thalassaemia and have completed a treatment period in an etavopivat study. |
Principal Investigator(s) 1. Bernhard Ogutu Site(s) in Kenya 1. KEMRI Kondele Children\'s Hospital (Kisumu county) 2. Center for Research in Therapeutic Sciences (CREATES) (Kisumu county) 3. Gertrudes Childrens Hospital (Nairobi City county) 4. KEMRI Siaya Clinical Research Annex (Siaya county) 5. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) 6. KEMRI WALTER REED KERICHO (Kericho county) 7. KEMRI/ WRAIR-Africa, Kombewa Clinical Research Center (Kisumu county) |
09-12-2025 |
View |
34. |
ECCT/25/05/02 | Hibiscus 2 - Site 251 A global phase 3, randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in adolescents and adults with sickle cell disease. |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 251 - Ahero Clinical Trails Unit, CREATES Strathmore University (Kisumu county) |
16-12-2025 |
View |
35. |
ECCT/25/05/01 | Sparkle Study Site 1403 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive CrisesA phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
18-12-2025 |
View |
36. |
ECCT/25/04/07 | Server migration Server Migration |
Principal Investigator(s) 1. Server Migration Server Migration Site(s) in Kenya Server Migration |
30-04-2025 |
View |
37. |
ECCT/25/03/07 | Sparkle - Site 1405 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Prof Videlis Nduba Site(s) in Kenya 1. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. Gertrudes Children’s Hospital (Nairobi City county) 6. Victoria Biomedical Research Institute (Kisumu county) |
16-09-2025 |
View |
38. |
ECCT/25/03/06 | Sparkle Study-Site 1404 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Godfrey Allan Otieno Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) 2. Ahero Clinical trials Unit (Kisumu county) 3. International Cancer institute (Uasin Gishu county) 4. Kondele Childrens Hospital (Kisumu county) 5. KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Gertrudes Children’s Hospital (Nairobi City county) |
26-11-2025 |
View |
39. |
ECCT/25/03/05 | Sparkle Study -Site 1402 A phase III, Multicenter, Randomized, Placebo Controlled, Double blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) versus placebo, with or without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients with Frequent Vaso-Occlusive Crises |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. Site 1401: Victoria Biomedical Research Institute (Kisumu county) 2. Site 1402: Ahero Clinical trials Unit (Kisumu county) 3. Site 1403: International Cancer Institute (Uasin Gishu county) 4. Site 1404: Kondele Childrens Hospital (Kisumu county) 5. Site 1405: KEMRI/CRDR KEMRI Clinical Research Annex (Siaya county) 6. Site 1406: Gertrude’s Children’s Hospital. (Nairobi City county) |
16-12-2025 |
View |
40. |
ECCT/25/04/01 | PHASE 2/3 OF SII-TCV(B) A PHASE 2/3, DOUBLE-BLIND, RANDOMIZED, ACTIVE CONTROLLED STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY AND IMMUNE NON-INTERFERENCE OF A BIVALENT CONJUGATE VACCINE AGAINST SALMONELLA ENTERICA SEROVARS TYPHI AND PARATYPHI A IN HEALTHY INFANTS AGED 9 TO 12 MONTHS |
Principal Investigator(s) 1. WALTER OTIENO Site(s) in Kenya VICTORIA BIOMEDICAL RESEARCH INSTITUTE |
07-10-2025 |
View |